Table 3. Associations of Alu and LINE-1 methylation status with clinicopathologic features of invasive breast cancer.

Characteristics	Alu		P value	LINE-1		P value
	Hypomethylated (<20.2%)	Methylated (≥20.2%)		Hypomethylated (<59.4%)	Methylated (≥59.4%)
Age			0.454			0.136
<50 years	42 (55.3)	51 (49.5)		41 (46.1)	52 (57.8)
≥50 years	34 (44.7)	52 (50.5)		48 (53.9)	38 (42.2)
T stage			0.446			0.547
T1	35 (46.1)	41 (39.8)		40 (44.9)	36 (40.0)
T2 & T3	41 (53.9)	62 (60.2)		49 (55.1)	54 (60.0)
N stage			0.446			0.173
N0	42 (55.3)	63 (61.2)		57 (64.0)	49 (53.3)
N1–N3	34 (44.7)	40 (38.8)		32 (36.0)	42 (46.7)
Histologic grade			0.640			0.214
Low (I & II)	26 (34.2)	39 (37.9)		28 (31.5)	37 (41.1)
High (III)	50 (65.8)	64 (62.1)		61 (68.5)	53 (58.9)
Lymphatic invasion			0.366			0.453
Absent	39 (51.3)	60 (58.3)		52 (58.4)	47 (52.2)
Present	37 (48.7)	43 (41.7)		37 (41.6)	43 (47.8)
Venous invasion			0.460			0.444
Absent	72 (94.7)	100 (97.1)		87 (97.8)	85 (94.4)
Present	4 (5.3)	3 (2.9)		2 (2.2)	5 (5.6)
P53 overexpression			0.429			0.028
Negative	47 (61.8)	70 (68.0)		51 (57.3)	66 (73.3)
Positive	29 (38.2)	33 (32.0)		38 (42.7)	24 (26.7)
Ki-67			0.437			0.442
<20%	26 (34.2)	42 (40.8)		31 (34.8)	37 (41.1)
≥20%	50 (65.8)	61 (59.2)		58 (65.2)	53 (58.9)
ER			0.006			<0.001
Negative	44 (57.9)	38 (36.9)		54 (60.7)	28 (31.1)
Positive	32 (42.1)	65 (63.1)		35 (39.3)	62 (68.9)
PR			0.095			0.011
Negative	47 (61.8)	50 (48.5)		57 (64.0)	40 (44.4)
Positive	29 (38.2)	53 (51.5)		32 (36.0)	50 (55.6)
ERBB2 amplification			0.354			0.006
Negative	43 (56.6)	66 (64.1)		45 (50.6)	64 (71.1)
Positive	33 (43.4)	37 (35.9)		44 (49.4)	26 (28.9)